Two metaanalyses of dual treatment for genotypes 2 and 3 which included 7 and 8 studies respectively concluded that overall SVR among patients with genotype 2 was 74% while for patients with genotype 3 it was 68%.
Dos metanálisis de tratamiento dual en genotipos 2 y 3 que incluyeron 7 y 8 estudios respectivamente, concluyeron que la RVS global en genotipos 2 era 74% y genotipo 3 de 68%.